Close Menu

HIV

The study, which sequenced and characterized 20 individual genomes, is part of a larger effort at Duke that aims to sequence around 200 genomes and 500 exomes from various disease cohorts including schizophrenia, epilepsy, ALS, and HIV.

Lab21 will offer the service from its UK operations "with immediate effect," and eventually plans to offer the test as part of its comprehensive HIV service at its US facility in Greenville, SC.

The multi-center research project will use sequencing, expression analysis, and a range of other systems biology approaches to understand early immune responses to HIV.

At AACC, Rheonix presented three research studies demonstrating its integrated sample prep and PCR testing platform. In addition, the company reiterated its intent to seek regulatory clearance in the US for a warfarin sensitivity genotyping test by the end of the year; followed by a regulatory submission in China for an HPV test.

The study supports the idea of more widespread nucleic acid-based HIV diagnostic testing, which could be a boon for Gen-Probe and Novartis Diagnostics, which offer the only approved NAT for qualitative HIV diagnosis in the US.

The company will use the cash to continue developing in vitro diagnostic assays for its "chemistry and reagent device," or CARD — which integrates sample preparation, nucleic acid amplification, and endpoint detection all on a single microfluidics-based, point-of-care polymeric module.

Marine Biochem's enzymes are being used in diagnostic kits sold by Siemens and sample-prep kits being tested by another unnamed company — relationships Marine Biochem hopes will help spark its transition from a B2B vendor to a company that sells research tools directly to end users.

The technology may enable a very stable diagnostic method to detect nucleic acids without using PCR, and has so far been demonstrated to detect anthrax.

Although the collaboration is aimed at increasing physician knowledge of genomic testing associated with all HIV drugs, it appears to have stemmed from lower-than-expected sales of Pfizer's CCR5-antagonist Selzentry.

The funds will support development of a high-throughput platform for screening infectious disease treatments.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.